dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Rischin, Danny |
dc.contributor.author | Harrington, Kevin |
dc.contributor.author | Greil, Richard |
dc.contributor.author | Soulières, Denis |
dc.contributor.author | Tahara, Makoto |
dc.contributor.author | de Castro Junior, Gilberto |
dc.contributor.author | Braña Garcia, Irene |
dc.date.accessioned | 2022-08-18T09:13:28Z |
dc.date.available | 2022-08-18T09:13:28Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, et al. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol. 2022 May;128:105815. |
dc.identifier.issn | 1879-0593 |
dc.identifier.uri | https://hdl.handle.net/11351/8013 |
dc.description | Immunoteràpia; Pembrolizumab; Qualitat de vida |
dc.description.sponsorship | Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Oral Oncology;128 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Cap - Càncer - Tractament |
dc.subject | Coll - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Squamous Cell Carcinoma of Head and Neck |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.oraloncology.2022.105815 |
dc.subject.decs | carcinoma de células escamosas de cabeza y cuello |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1016/j.oraloncology.2022.105815 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rischin D] Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. [Harrington KJ] Radiotherapy and Imaging, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom. [Greil R] Hematology and Medical Oncology, Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria. [Soulières D] Haematology/Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, Canada. [Tahara M] Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [de Castro G Jr] Medical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. [Braña I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 35381576 |
dc.identifier.wos | 000792907400009 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |